Associated Professor of Pathology, Tehran University of Medical Sciences and Health Services, Imam Khomeini Hospital, Tehran, Iran
Abstract
Introduction & Objective: The epidermal growth factor receptor gene (HER-2) plays an important role in cell transformation and tumorgenesis. The presence of HER-2 gene generally predicts a good response to anthracycline-based agents and therapies that specifically target HER-2 (Herceptin). Materials & Methods: Comparison between IHC and CISH methods for assessment of HER-2 status was performed on 38 women suffering from invasive ductal carcinoma. Data analysis was performed by pair wise grouped statistical method. Results: There was a good correlation between IHC and CISH methods for assessment of HER-2 status in 92.1% of cases (Kappa=0.938, P
Ensani,F , M,K , Davanloo,M , Irvanloo,G and Khazaeipour,Z . (2009). Comparison between Immunohistochemistry and Chromogenic in Situ Hybridization Method in Assessment of HER-2 Status in Breast Cancer. Iranian Journal of Surgery, 17(Winter), 41-48.
MLA
Ensani,F , , M,K , , Davanloo,M , , Irvanloo,G , and Khazaeipour,Z . "Comparison between Immunohistochemistry and Chromogenic in Situ Hybridization Method in Assessment of HER-2 Status in Breast Cancer", Iranian Journal of Surgery, 17, Winter, 2009, 41-48.
HARVARD
Ensani F, M K, Davanloo M, Irvanloo G, Khazaeipour Z. (2009). 'Comparison between Immunohistochemistry and Chromogenic in Situ Hybridization Method in Assessment of HER-2 Status in Breast Cancer', Iranian Journal of Surgery, 17(Winter), pp. 41-48.
CHICAGO
F Ensani, K M, M Davanloo, G Irvanloo and Z Khazaeipour, "Comparison between Immunohistochemistry and Chromogenic in Situ Hybridization Method in Assessment of HER-2 Status in Breast Cancer," Iranian Journal of Surgery, 17 Winter (2009): 41-48,
VANCOUVER
Ensani F, M K, Davanloo M, Irvanloo G, Khazaeipour Z. Comparison between Immunohistochemistry and Chromogenic in Situ Hybridization Method in Assessment of HER-2 Status in Breast Cancer. Iranian Journal of Surgery. 2009;17(Winter):41-48.
